Organisation paid for research Program year 2025 Source: CMS Open Payments

Intercoastal Medical Group

Neither a doctor nor a teaching hospital

Research payments

$7,575,213

783 payments

Through program year 2025, Intercoastal Medical Group is reported as receiving $7,575,213 in research payments, across 783 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $447,149 21
2024 Research $396,639 8
2023 Research $1,006,433 10
2022 Research $1,474,948 40
2021 Research $2,346,165 201
2020 Research $1,037,447 295
2019 Research $866,432 208

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $5,997,229 33 payments
  2. Novo Nordisk AS $715,564 476 payments
  3. Amgen Inc. $538,806 39 payments
  4. CSL Behring $195,381 85 payments
  5. Portola Pharmaceuticals, Inc. $46,245 123 payments
  6. ITI, Inc. $32,262 11 payments
  7. E.R. Squibb & Sons, L.L.C. $15,700 2 payments
  8. Alexion Pharmaceuticals, Inc. $9,300 2 payments
  9. ACADIA Pharmaceuticals Inc $9,200 2 payments
  10. United Therapeutics Corporation $9,149 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $3,479,249 9 payments
  2. Assessment of Safety, Tolerability and Efficacy of Ly3002813 Alone and in Combination With Ly3202626 in Early Symptomatic Alzheimers Disease $1,211,038 7 payments
  3. A Study of Donanemab (Ly3002813) in Participants With Early Alzheimer's Disease (Trailblazer-Alz 2) $963,422 2 payments
  4. Ex9536-4388 $715,564 476 payments
  5. FOURIER OLE (Ph 4) $193,474 8 payments
  6. A Randomized, Double-Blinded Study to Evaluate the Efficacy and Safety of Mevidalen in Patients With Alzheimer's Disease $189,508 3 payments
  7. A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome $181,619 77 payments
  8. Donanemab Follow-On Study: Safety, Tolerability, and Efficacy in Symptomatic Alzheimer's Disease With Validation of Remote Neuropsychological Assessments $132,714 5 payments
  9. A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity $112,553 1 payment
  10. 20160250-FOURIER OLE (Ph 4) $61,795 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record